{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:52:02Z","timestamp":1790599922208,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jns.2022.120332","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:46:51Z","timestamp":1656982011000},"page":"120332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Psychedelic drugs for psychiatric disorders"],"prefix":"10.1016","volume":"440","author":[{"given":"Sabrina Correa","family":"da Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Oesterle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa A.","family":"Rummans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Richelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jns.2022.120332_bb0005","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"10.1016\/j.jns.2022.120332_bb0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/YCO.0000000000000467","article-title":"How do psychedelics work?","volume":"32","author":"Carhart-Harris","year":"2019","journal-title":"Curr. Opin. Psychiatry."},{"issue":"3","key":"10.1016\/j.jns.2022.120332_bb0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","article-title":"A review of the clinical effects of psychotomimetic agents","volume":"66","author":"Osmond","year":"1957","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2022.120332_bb0025","article-title":"Plants of the gods\u202f: their sacred, healing, and hallucinogenic powers","author":"Schultes","year":"2001","journal-title":"Phytochemistry."},{"issue":"4","key":"10.1016\/j.jns.2022.120332_bb0030","first-page":"64","article-title":"Entheogenic rituals, shamanism and green psychology","volume":"2013","author":"Metzner","year":"2013","journal-title":"Eur. J. Ecopsychol."},{"issue":"3","key":"10.1016\/j.jns.2022.120332_bb0035","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2307\/4110029","article-title":"Plants of the Gods: Origins of Hallucinogenic Use","volume":"35","author":"Brenan","year":"1980","journal-title":"Kew Bull."},{"issue":"4","key":"10.1016\/j.jns.2022.120332_bb0040","first-page":"442","article-title":"Sacred sites: cultural values and management issues","volume":"13","author":"Swan","year":"1984","journal-title":"Int. Perspect. Cult. Park. Proc. first world Conf."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jaarel\/LII.1.93","article-title":"The significance of the American Indian religious freedom act of 1978","volume":"52","author":"Michaelsen","year":"1984","journal-title":"J. Am. Acad. Relig."},{"key":"10.1016\/j.jns.2022.120332_bb0050","series-title":"American Indian Religious Freedom Act (AIRFA; 1978). Encycl United States Indian Policy Law","author":"Finkelman","year":"2014"},{"issue":"9","key":"10.1016\/j.jns.2022.120332_bb0055","doi-asserted-by":"crossref","DOI":"10.1176\/ajp.137.9.1142-a","article-title":"Psychedelic drugs reconsidered","volume":"137","author":"Frosch","year":"1980","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2022.120332_bb0060","article-title":"The discovery of LSD and subsequent investigations on naturally occurring hallucinogens","author":"Hofmann","year":"1970","journal-title":"Discov. Biol. Psychiatry."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/dta.2292","article-title":"MDA, MDMA, and other \u201cmescaline-like\u201d substances in the US military\u2019s search for a truth drug (1940s to 1960s)","volume":"10","author":"Passie","year":"2018","journal-title":"Drug. Test. Anal."},{"issue":"2","key":"10.1016\/j.jns.2022.120332_bb0070","doi-asserted-by":"crossref","first-page":"139","DOI":"10.31887\/DCNS.2019.21.2\/dnutt","article-title":"Psychedelic drugs\u2014a new era in psychiatry?","volume":"21","author":"Nutt","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jns.2022.120332_bb0075","series-title":"BOOK - Acid Dreams: The Complete Social History of LSD: The CIA, the Sixties, and Beyond Paperback \u2013 January 21, 1994 by Martin A. Lee (Author)","article-title":"Acid Dreams. Complet. Soc. Hist. LSD CIA, Sixties, Beyond","author":"Lee","year":"2007"},{"issue":"2","key":"10.1016\/j.jns.2022.120332_bb0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/02791072.2015.1128580","article-title":"The history of MDMA as an underground drug in the United States, 1960\u20131979","volume":"48","author":"Passie","year":"2016","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jns.2022.120332_bb0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology."},{"issue":"9","key":"10.1016\/j.jns.2022.120332_bb0090","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1177\/0269881115598338","article-title":"Psilocybin, psychological distress, and suicidality","volume":"29","author":"Hendricks","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"7 July","key":"10.1016\/j.jns.2022.120332_bb0095","article-title":"Persistent psychosis associated with Salvia divinorum use","volume":"166","author":"Przekop","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.jns.2022.120332_bb0100","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","article-title":"Adverse reactions to psychedelic drugs. A review of the literature","volume":"172","author":"Strassman","year":"1984","journal-title":"J. Nerv. Ment. Dis."},{"issue":"3","key":"10.1016\/j.jns.2022.120332_bb0105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/02791072.2017.1312643","article-title":"Psychedelics, personality and political perspectives","volume":"49","author":"Nour","year":"2017","journal-title":"J. Psychoactive Drugs"},{"issue":"3","key":"10.1016\/j.jns.2022.120332_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1192\/bjp.bp.116.194738","article-title":"Psychedelics and the science of self-experience","volume":"210","author":"Nour","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jns.2022.120332_bb0115","author":"U.S. Department of Justice: Drug Enforcement Administration"},{"issue":"8","key":"10.1016\/j.jns.2022.120332_bb0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jns.2022.120332_bb0125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1192\/bjp.186.6.457","article-title":"Can psychedelics have a role in psychiatry once again?","volume":"186","author":"Sessa","year":"2005","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0130","article-title":"Turn on and tune in to evidence-based psychedelic research. The Lancet","volume":"2","author":"Sessa","year":"2015","journal-title":"Psychiatry."},{"key":"10.1016\/j.jns.2022.120332_bb0135","unstructured":"Studies MA for P. Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD (MPVA6). https:\/\/clinicaltrials.gov\/show\/NCT04784143. Last Update Posted: November 17, 2021."},{"key":"10.1016\/j.jns.2022.120332_bb0140","unstructured":"Remick S. MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD (VALLMDMA_001). https:\/\/clinicaltrials.gov\/show\/NCT04264026. Last Update Posted\u202f: August 12, 2021."},{"key":"10.1016\/j.jns.2022.120332_bb0145","author":"Benjamin Kelmendi, MD, Yale University"},{"key":"10.1016\/j.jns.2022.120332_bb0150","unstructured":"Belinda Tan. Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy. https:\/\/clinicaltrials.gov\/show\/NCT05274230. Last Update Posted: May 2, 2022."},{"key":"10.1016\/j.jns.2022.120332_bb0155","unstructured":"Scott T Aaronson. The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation. https:\/\/clinicaltrials.gov\/show\/NCT05220410. Last Update Posted: February 8, 2022."},{"key":"10.1016\/j.jns.2022.120332_bb0160","unstructured":"Trisha Suppes, Scott Aaronson, An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD). https:\/\/clinicaltrials.gov\/show\/NCT04433858. Last Update Posted: December 21, 2021."},{"key":"10.1016\/j.jns.2022.120332_bb0165","author":"Aaronson"},{"issue":"4","key":"10.1016\/j.jns.2022.120332_bb0170","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of \u00b13,4-methylenedioxymethamphetamine- assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.jns.2022.120332_bb0175","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2022.120332_bb0180","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/0269881118806297","article-title":"3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial","volume":"32","author":"Ot\u2019alora","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jns.2022.120332_bb0185","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/npp.2017.171","article-title":"MDMA impairs both the encoding and retrieval of emotional recollections","volume":"43","author":"Doss","year":"2018","journal-title":"Neuropsychopharmacology."},{"issue":"8","key":"10.1016\/j.jns.2022.120332_bb0190","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/0269881117711712","article-title":"Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy","volume":"31","author":"Wagner","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0195","doi-asserted-by":"crossref","first-page":"20442","DOI":"10.1038\/s41598-020-75706-1","article-title":"MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study","volume":"10","author":"Wolfson","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.jns.2022.120332_bb0200","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","article-title":"Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials","volume":"237","author":"Jerome","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jns.2022.120332_bb0205","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pnpbp.2015.03.011","article-title":"MDMA-assisted therapy: a new treatment model for social anxiety in autistic adults","volume":"64","author":"Danforth","year":"2016","journal-title":"Prog. Neuro. Psychopharmacol. Biol. Psychiatry."},{"issue":"11","key":"10.1016\/j.jns.2022.120332_bb0210","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","article-title":"Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study","volume":"235","author":"Danforth","year":"2018","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.jns.2022.120332_bb0215","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"issue":"9160","key":"10.1016\/j.jns.2022.120332_bb0220","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(05)66940-1","article-title":"Toxic effect of MDMA on brain serotonin neurons","volume":"353","author":"Morgan","year":"1999","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0225","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-8993(88)91309-1","article-title":"Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration","volume":"446","author":"Ricaurte","year":"1988","journal-title":"Brain Res."},{"issue":"9160","key":"10.1016\/j.jns.2022.120332_bb0230","doi-asserted-by":"crossref","first-page":"P1269","DOI":"10.1016\/S0140-6736(05)66941-3","article-title":"Toxic effect of MDMA on brain serotonin neurons","volume":"353","author":"Kuikka","year":"1999","journal-title":"Lancet."},{"issue":"1-3","key":"10.1016\/j.jns.2022.120332_bb0235","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0378-4274(01)00511-2","article-title":"Specific neurotoxicity of chronic use of ecstasy","volume":"127","author":"Obrocki","year":"2002","journal-title":"Toxicol. Lett."},{"issue":"4","key":"10.1016\/j.jns.2022.120332_bb0240","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archgenpsychiatry.2011.156","article-title":"Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users","volume":"69","author":"Di Iorio","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jns.2022.120332_bb0245","first-page":"275","article-title":"The psychedelic drug therapies","volume":"20","author":"Grinspoon","year":"1981","journal-title":"Curr. Psychiatr. Ther."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0250","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/ajp.126.1.59","article-title":"A clinical study of LSD treatment in alcoholism","volume":"126","author":"Ludwig","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2022.120332_bb0255","first-page":"144","article-title":"LSD-assisted psychotherapy with terminal cancer patients","volume":"9","author":"Pahnke","year":"1969","journal-title":"Curr. Psychiatr. Ther."},{"key":"10.1016\/j.jns.2022.120332_bb0260","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","article-title":"Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials","volume":"10","author":"Fuentes","year":"2020","journal-title":"Front. Psychiatry."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0265","first-page":"21","article-title":"A review of the use of LSD for the patient near death","volume":"3","author":"Sheehan","year":"1972","journal-title":"Psychiatr. Forum."},{"issue":"533","key":"10.1016\/j.jns.2022.120332_bb0270","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1192\/bjp.116.533.443","article-title":"A controlled study of LSD treatment in alcoholism and neurosis","volume":"116","author":"Denson","year":"1970","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jns.2022.120332_bb0275","article-title":"A complete international bibliography","author":"Passie","year":"1931","journal-title":"Psycholytic. Psychedelic. Ther. Res."},{"issue":"17","key":"10.1016\/j.jns.2022.120332_bb0280","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport."},{"issue":"3","key":"10.1016\/j.jns.2022.120332_bb0285","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/appi.psychotherapy.1966.20.3.415","article-title":"LSD in psychotherapy and alcoholism","volume":"20","author":"Abramson","year":"1966","journal-title":"Am. J. Psychother."},{"issue":"2","key":"10.1016\/j.jns.2022.120332_bb0290","article-title":"LSD in the Treatment of Alcoholics *. Pharmacopsychiatry. 1971; \"LSD in the Treatment of Alcoholics,\"","volume":"4","author":"Kurland","year":"1971","journal-title":"Pharmakopsychiatrie Neuro-Psychopharmakologie."},{"key":"10.1016\/j.jns.2022.120332_bb0295","first-page":"85","article-title":"LSD as an adjunct to psychotherapy with alcoholics","volume":"50","author":"Rolo","year":"1960","journal-title":"J. Psychol. Int. Appl."},{"issue":"4","key":"10.1016\/j.jns.2022.120332_bb0300","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00006842-196807000-00014","article-title":"The Use of LSD in Psychotherapy and Alcoholism","volume":"30","author":"Blaine","year":"1968","journal-title":"Psychosom. Med."},{"issue":"4","key":"10.1016\/j.jns.2022.120332_bb0305","first-page":"149","article-title":"Psychedelic drugs and mystical experience","volume":"5","author":"Pahnke","year":"1969","journal-title":"Int. Psychiatry Clin."},{"issue":"7","key":"10.1016\/j.jns.2022.120332_bb0310","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jns.2022.120332_bb0315","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/pmt-2017-0068","article-title":"Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?","volume":"8","author":"Whelan","year":"2018","journal-title":"Pain. Manag."},{"issue":"12","key":"10.1016\/j.jns.2022.120332_bb0320","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0325","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.jns.2022.120332_bb0330","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1038\/npp.2016.82","article-title":"LSD acutely impairs fear recognition and enhances emotional empathy and sociality","volume":"41","author":"Dolder","year":"2016","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jns.2022.120332_bb0335","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","article-title":"Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study","volume":"41","author":"Hutten","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.jns.2022.120332_bb0340","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.54","article-title":"Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects","volume":"7","author":"Mueller","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2022.120332_bb0345","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","article-title":"Long-lasting subjective effects of LSD in normal subjects","volume":"235","author":"Schmid","year":"2018","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.jns.2022.120332_bb0350","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","article-title":"Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers","volume":"86","author":"Bershad","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"43","key":"10.1016\/j.jns.2022.120332_bb0355","article-title":"Psychedelic microdosing benefits and challenges: An empirical codebook","volume":"16","author":"Anderson","year":"2019","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.jns.2022.120332_bb0360","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey","volume":"10","author":"Garcia-Romeu","year":"2020","journal-title":"Front. Psychiatry."},{"key":"10.1016\/j.jns.2022.120332_bb0365","article-title":"A new era of treating substance use disorders with psychedelics","author":"B. A, R. G, P. H, A. G-R, M. B, S.S. F","year":"2019","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.jns.2022.120332_bb0370","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3389\/fphar.2018.00733","article-title":"Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development","volume":"9","author":"E.E. S","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.jns.2022.120332_bb0375","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"M.W. J, R.R. G","year":"2017","journal-title":"Neurotherapeutics."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0380","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol. Abuse."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0385","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2022.120332_bb0390","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jns.2022.120332_bb0395","first-page":"S90","article-title":"A single dose of psilocybin produces substantial and enduring decreases in anxiety and depression in patients with a life-threatening cancer diagnosis: a randomized double-blind trial","volume":"40","author":"Griffiths","year":"2015","journal-title":"Neuropsychopharmacology."},{"issue":"12","key":"10.1016\/j.jns.2022.120332_bb0400","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jns.2022.120332_bb0405","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpsychires.2021.03.002","article-title":"Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review","volume":"137","author":"Romeo","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"11","key":"10.1016\/j.jns.2022.120332_bb0410","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry."},{"issue":"11","key":"10.1016\/j.jns.2022.120332_bb0415","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jns.2022.120332_bb0420","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.jns.2022.120332_bb0425","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"R.L. C-H, M. BB, J. R, C.M.J. D, D. E, M. K","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0430","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jns.2022.120332_bb0435","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0269881119895520","article-title":"Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression","volume":"34","author":"Mertens","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jns.2022.120332_bb0440","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","article-title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression","volume":"142","author":"Roseman","year":"2018","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.jns.2022.120332_bb0445","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","article-title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin","volume":"10","author":"Barrett","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.jns.2022.120332_bb0450","first-page":"1","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2020","journal-title":"JAMA Psychiatry."},{"issue":"4","key":"10.1016\/j.jns.2022.120332_bb0455","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jns.2022.120332_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2014.09.245","article-title":"Psychedelic-facilitated smoking cessation: an online survey","volume":"146","author":"Garcia-Romeu","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"15","key":"10.1016\/j.jns.2022.120332_bb0465","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2022.120332_bb0470","author":"National Survey on Drug Use and Health"},{"issue":"9518","key":"10.1016\/j.jns.2022.120332_bb0475","first-page":"1214","article-title":"Reviving research into psychedelic drugs","volume":"367","author":"The Lancet","year":"2006","journal-title":"Lancet."},{"key":"10.1016\/j.jns.2022.120332_bb0480","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/164_2018_177","article-title":"Self-experiments with psychoactive substances: a historical perspective","volume":"252","author":"Passie","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/j.jns.2022.120332_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2022.120332_bb0490","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62878","article-title":"Self-blinding citizen science to explore psychedelic microdosing","volume":"10","author":"Szigeti","year":"2021","journal-title":"Elife."},{"issue":"9838","key":"10.1016\/j.jns.2022.120332_bb0495","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(12)60600-X","article-title":"Shaping the renaissance of psychedelic research","volume":"380","author":"Sessa","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.jns.2022.120332_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2016.10.010","article-title":"Addressing the need for rigor in the rebirth of hallucinogen research","author":"Nichols","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jns.2022.120332_bb0505","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuropharm.2017.11.029","article-title":"Studies with psychedelic drugs in human volunteers","volume":"142","author":"Sellers","year":"2018","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.jns.2022.120332_bb0510","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/shm\/hkl039","article-title":"\u201cHitting highs at rock bottom\u201d: LSD treatment for alcoholism, 1950-1970","volume":"19","author":"Dyck","year":"2006","journal-title":"Soc. Hist. Med."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0515","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design","volume":"25","author":"Rush","year":"2004","journal-title":"Control. Clin. Trials"},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0520","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2022.120332_bb0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229067","article-title":"Self-reported negative outcomes of psilocybin users: a quantitative textual analysis","volume":"15","author":"Bienemann","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2022.120332_bb0530","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long-term effects of psychedelic drugs: a systematic review","volume":"113","author":"Aday","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"6","key":"10.1016\/j.jns.2022.120332_bb0535","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jns.2022.120332_bb0540","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/02791072.1998.10399712","article-title":"Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions","volume":"30","author":"Callaway","year":"1998","journal-title":"J. Psychoactive Drugs"},{"issue":"3","key":"10.1016\/j.jns.2022.120332_bb0545","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.107.129056","article-title":"Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics","volume":"323","author":"Farr\u00e9","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.jns.2022.120332_bb0550","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/jpet.114.222356","article-title":"Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects","volume":"353","author":"Schmid","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22001940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22001940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:59:24Z","timestamp":1758383964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22001940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":110,"alternative-id":["S0022510X22001940"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120332","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelic drugs for psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120332"}}